Literature DB >> 23385274

Management of transgenderism.

Norman P Spack1.   

Abstract

Gender identity disorder (transgenderism) is poorly understood from both mechanistic and clinical standpoints. Awareness of the condition appears to be increasing, probably because of greater societal acceptance and available hormonal treatment. Therapeutic options include hormone and surgical treatments but may be limited by insurance coverage because costs are high. For patients seeking male-to-female (MTF) change, hormone treatment includes estrogens, finasteride, spironolactone, and gonadotropin-releasing hormone (GnRH) analogs. Surgical options include feminizing genital and facial surgery, breast augmentation, and various fat transplantations. For patients seeking a female-to-male (FTM) gender change, medical therapy includes testosterone and GnRH analogs and surgical therapy includes mammoplasty and phalloplasty. Medical therapy for both FTM and MTF can be started in early puberty, although long-term effects are not known. All patients considering treatment need counseling and medical monitoring.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385274     DOI: 10.1001/jama.2012.165234

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

Review 1.  Agreement between medical records and self-reports: Implications for transgender health research.

Authors:  Joseph Gerth; Tracy Becerra-Culqui; Andrew Bradlyn; Darios Getahun; Enid M Hunkeler; Timothy L Lash; Andrea Millman; Rebecca Nash; Virginia P Quinn; Brandi Robinson; Douglas Roblin; Michael J Silverberg; Vin Tangpricha; Suma Vupputuri; Michael Goodman
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

2.  Medical treatment in gender dysphoric adolescents endorsed by SIAMS-SIE-SIEDP-ONIG.

Authors:  A D Fisher; J Ristori; E Bandini; S Giordano; M Mosconi; E A Jannini; N A Greggio; A Godano; C Manieri; C Meriggiola; V Ricca; D Dettore; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-05-27       Impact factor: 4.256

3.  Is puberty delaying treatment 'experimental treatment'?

Authors:  Simona Giordano; Søren Holm
Journal:  Int J Transgend Health       Date:  2020-04-11

4.  Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.

Authors:  Hannan M Braun; Jury Candelario; Courtney L Hanlon; Eddy R Segura; Jesse L Clark; Judith S Currier; Jordan E Lake
Journal:  LGBT Health       Date:  2017-09-06       Impact factor: 4.151

Review 5.  Oestrogen and anti-androgen therapy for transgender women.

Authors:  Vin Tangpricha; Martin den Heijer
Journal:  Lancet Diabetes Endocrinol       Date:  2016-12-02       Impact factor: 32.069

6.  Fertility Counseling for Transgender AYAs.

Authors:  Janella Hudson; Leena Nahata; Elizabeth Dietz; Gwendolyn P Quinn
Journal:  Clin Pract Pediatr Psychol       Date:  2017-03-16

Review 7.  Hormone therapy for transgender patients.

Authors:  Cécile A Unger
Journal:  Transl Androl Urol       Date:  2016-12

8.  Dermatologic care of the transgender patient.

Authors:  B A Ginsberg
Journal:  Int J Womens Dermatol       Date:  2016-12-22

9.  Advocacy for Gender Affirming Care: Learning from the Injectable Estrogen Shortage.

Authors:  Sophia Geffen; Tim Horn; Kimberleigh Joy Smith; Sean Cahill
Journal:  Transgend Health       Date:  2018-03-01

10.  Determinants of and Barriers to Hormonal and Surgical Treatment Receipt Among Transgender People.

Authors:  R Craig Sineath; Cory Woodyatt; Travis Sanchez; Shawn Giammattei; Theresa Gillespie; Enid Hunkeler; Ashli Owen-Smith; Virginia P Quinn; Douglas Roblin; Robert Stephenson; Patrick S Sullivan; Vin Tangpricha; Michael Goodman
Journal:  Transgend Health       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.